Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #120610 on Anavex Life Sciences Corp (AVXL)
123tom
09/18/17 2:45 AM
#120611 RE: XenaLives #120610
Investor2014
09/18/17 3:08 AM
#120612 RE: XenaLives #120610
Fireman02360
09/18/17 6:23 AM
#120613 RE: XenaLives #120610
xodcode
09/18/17 6:37 AM
#120614 RE: XenaLives #120610
SquealingSquid
09/18/17 6:56 AM
#120615 RE: XenaLives #120610
nidan7500
09/18/17 7:57 AM
#120619 RE: XenaLives #120610
These methods have been used with some of the newer immunological therapies. It may also be used in other drugs targeted against specific molecular defects. Seamless designs are particularly advantageous for drugs that work in a variety of diseases, allowing rapid evaluation of the drug and potential approval under our accelerated approval pathway. These new approaches are also highly consistent with the goals of the 21st Century Cures Act and the recently passed FDA Reauthorization Act.
samk
09/18/17 9:17 AM
#120623 RE: XenaLives #120610